Bli medlem
Bli medlem

Du är här


Nexstim Oyj: Conversion of the convertible bond entered into between Nexstim Plc and Bracknor to shares and issuance of shares pursuant to the financing arrange

Company announcement, Helsinki, 24 October 2016 at 9 pm

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim
" or the "Company
"), a medical technology company with a pioneering navigated non-invasive
brain stimulation system, announces that, pursuant to the authorisations
received from the Company's Extraordinary General Meeting on 18 August 2016
and the financing arrangement entered into with Bracknor Investment which was
announced on 21 July, the Board of Directors of the Company has today
resolved to approve Bracknor's request to convert EUR 75,000 of the
convertible bond to Company's shares at issue price of EUR 0,234515. The
Board of Director's has resolved to transfer a total of 319,808 new shares of
the Company to Bracknor. The board of directors of the Company has also
resolved to issue 1,271,068 new treasury shares to the Company itself without
payment and to list the new shares issued pursuant to the above resolutions.
The new shares will be listed approximately on 28thOctober 2016. After the
issuance the Company will have 1,298,213 treasury shares and the total number
of shares in the Company is 12,982,131.

Martin Jamieson, CEO

Further information is available on the website
www.nexstim.comor by telephone:


Martin Jamieson, CEO

UB Securities Oy
(Certified Adviser)
+358 (0)9 2538 0246

Consilium Strategic Communications
+44 (0)20
3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in
brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is
the first and only FDA cleared and CE marked system based on navigated
Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the
speech and motor cortices of the brain. Based on the same technology
platform, the Company has developed a system called Navigated Brain Therapy
(NBT®) which is CE marked for the treatment of chronic neuropathic pain,
major depression and stroke. Nexstim shares are listed on the Nasdaq First
North Finland and Nasdaq First North Sweden. For more information please

Nexstim Plc


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.